Advertisement


Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki

2022 ASCO Annual Meeting

Advertisement

Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The HERB trial is an investigator-initiated, multicenter, single-arm Phase II trial which evaluate the efficacy and the safety of trastuzumab deruxtecan, T-DXd, in patient with HER2-expressing biliary tract cancers. In 2016, when we began to design this study, there were no effective second-line chemotherapy regiments and no effective targeted therapies for biliary tract cancers. Moreover, even breast and gastric cancers, T-DXd did not have strong evidence, but the early efficacy signs of T-DXd in breast cancer and the HER2-positive rate in biliary tract cancer made us decide to conduct this trial. Before we ran the trial, we examined the tissue sample of more than 400 biliary tract cancer cases by HER2 testing and found that HER2 expression patterns were more similar to gastric cancer than breast cancer. We used the diagnostic criterion for this trial. Patient was screened in 30 Japanese centers taking part in the SCRUM-Japan project and the trial was conducted in five of these 30 centers. A key inclusion criteria was histologically confirmed unresectable or recurrent biliary tract cancer, centrally confirmed HER2-expressing status and refractory or intolerant to treatment, including gemcitabine. The primary endpoint was confirmed objective response rate in HER2-positive patient by blinded independent central review, BICR. During my year, we enrolled 32 patient, 24 HER2-positive, and eight were HER2-low-expressing. Two ineligible patients were excluded from the efficacy analysis. Of the 22 HER2-positive eligible patients, the primary endpoint of the confirmed objective response rate was 36.4%. Among the eight HER2-low-expressing patients, one patient achieved a partial response. The duration of response, progression-free survival and overall survival, was longer than we expected. In terms of adverse events, the most common adverse events were hematological toxicities such as anemia and neutrophil count decreased and white blood cell count decreased. They were more frequent than in clinical trials of T-DXd in other cancer types. Interstitial lung disease occurred in 25% of patient, including two grade-five cases. Also, we could not find obvious risk factors. We should pay attention to all this when we're using this drug, especially for biliary tract cancers. We think that T-DXd showed promising activity in HER2-expressing biliary tract cancers. Further evaluations are needed to confirm these findings in this patient population. On the other hand, such a large-scale trial is difficult for a limited population of HER2-positive biliary tract cancers, and we also discussed the way of drug approval based on the result of this study. I hope that such an effective drug will be available in our clinical practice.

Related Videos

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma (Abstract 4516).

Breast Cancer

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial lung disease; tumor targeting and payload release; drug resistance; and the urgent need to understand ADCs’ mechanisms of action to better sequence and combine drugs.

Breast Cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).

Sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Domenica Lorusso, MD, PhD, on Gynecologic Cancers: New Findings on Trabectedin vs Clinician’s Choice Chemotherapy

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype. Although trabectedin has demonstrated antitumor activity in relapsed platinum-sensitive disease, it does not appear to improve survival outcomes when compared with standard chemotherapy in the BRCA-mutated population (Abstract LBA5504).

Advertisement

Advertisement




Advertisement